Provided by Tiger Trade Technology Pte. Ltd.

Taysha Gene Therapies, Inc.

5.14
-0.0200-0.39%
Volume:121.50K
Turnover:633.12K
Market Cap:1.67B
PE:-12.46
High:5.26
Open:5.26
Low:5.14
Close:5.16
52wk High:7.30
52wk Low:2.71
Shares:325.83M
Float Shares:233.00M
Volume Ratio:0.63
T/O Rate:0.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4126
EPS(LYR):-0.3409
ROE:-47.05%
ROA:-23.82%
PB:4.32
PE(LYR):-15.08

Loading ...

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

GlobeNewswire
·
Apr 29

Taysha Gene Therapies to present new TSHA-102 preclinical data at ASGCT annual meeting

Reuters
·
Apr 28

Taysha Gene Therapies announces annual shareholder meeting

Reuters
·
Apr 22

Unusually active option classes on open April 16th

TIPRANKS
·
Apr 16

U.S. Small Caps Finish Mixed As Taysha Gene Therapies Leads, BRP Lags

Dow Jones
·
Apr 16

Buy Rating on Taysha Gene Therapies Driven by Strong Leadership, Strategic Positioning, and Attractive Risk‑Reward Upside

TIPRANKS
·
Apr 15

Taysha Gene Therapies President Sukumar Nagendran disposes 200,000 shares for $892,000

Reuters
·
Apr 14

Taysha Gene Therapies Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Apr 06

Taysha Gene Therapies price target raised to $17 from $14 at Canaccord

TIPRANKS
·
Apr 06

Taysha grants 300,000 RSUs under Nasdaq inducement plan for new hires

Reuters
·
Apr 03

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 03

Stock Track | Taysha Gene Therapies Soars 5.33% Intraday After Cantor Fitzgerald Issues Buy Rating

Stock Track
·
Mar 25

Taysha Gene Therapies (TSHA) Receives a Buy from Cantor Fitzgerald

TIPRANKS
·
Mar 25

Should Rett Breakthrough Status and Pivotal Trial Progress Require Action From Taysha Gene Therapies (TSHA) Investors?

Simply Wall St.
·
Mar 23

Taysha Gene Therapies (TSHA) Receives a Buy from Wells Fargo

TIPRANKS
·
Mar 22

Taysha Gene Therapies Advances Rett Program As Valuation Draws Investor Focus

Simply Wall St.
·
Mar 22

Taysha Gene Therapies Signals Momentum in Earnings Call

TIPRANKS
·
Mar 20

Taysha Gene Therapies Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 20

Analysts Are Bullish on These Healthcare Stocks: Collegium Pharmaceutical (COLL), Taysha Gene Therapies (TSHA)

TIPRANKS
·
Mar 20

Chardan Capital Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)

TIPRANKS
·
Mar 20